29
Jul
2019
Author: CoryTraina
22
Jul
2019
Bionest
Real World Evidence Replacing Some Clinical Trials?
Pharmaceutical companies have long used real-world data on drug performance to help justify their pricing decisions to payers. But now such real-world evidence (RWE), gathered from electronic medical records (EMRs), national patient registries and other patient databases, is increasingly being looked at as a way to make the case for new supplemental approvals and label...
15
Jul
2019
Bionest
News from ASCO: Part 2
In this post, we continue our report on some of the precision medicine approaches and initiatives we noted at ASCO. Neoantigens Revitalizing Cancer Vaccine Efforts Early efforts to create cancer vaccines aimed at increasing the immune system’s exposure to tumors, but the effectiveness of first-generation vaccines created by Dendreon and others was limited....
8
Jul
2019
Bionest
News from ASCO: Part 1
As we previously wrote, ASCO’s focus this year was on driving the benefits of precision medicine approaches in oncology to more patients. This was reflected in several ways in the news coming out of the conference, including: Progress Against Important, Difficult-to-Target Biomarkers The ASCO news was particularly good this year for patients with...
1
Jul
2019
Bionest
Building a Better Market for Biologics: The US vs. Europe
The advent of generics has dramatically impacted the cost of small molecule drugs following the expiry of the patent protection for the originator therapeutics, with the cost of a small molecule generic often as little as 10% of that of the originator drug. This price difference results from several factors, including lower R&D costs, fewer...
24
Jun
2019
Bionest
Liquid Biopsy Methods Showing Their Worth
The ability to detect and monitor mutational changes in tumors through a simple blood test has spurred considerable development within the field of liquid biopsy. While questions remain about the accuracy of such tests and the most relevant analyte to measure (i.e., circulating tumor DNA, cell free DNA, circulating tumor cells), liquid biopsy could offer...
20
Jun
2019
Bionest
Highlights from AAN: Part 2
We continue our report of interesting developments from the American Academy of Neurology meeting: Neuromyelytis Optica Spectrum Disorder (NMOSD) Interest in a rare disease called neuromyelytis optica spectrum disorder (NMOSD) appears to be growing. NMOSD is an autoimmune condition that causes swelling of the optic nerve and spinal cord, which can result in...
17
Jun
2019
Bionest
Highlights from AAN: Part 1
The Bionest team attended the American Academy of Neurology (AAN) in early May, where we heard exciting data presented in a number of neurological conditions. Among the highlights of this year’s conference: Transformative Success in Spinal Muscular Atrophy Spinal muscular atrophy (SMA) was a hot topic at AAN, with presentations of positive clinical...
10
Jun
2019
Bionest
Breaking Out of the Bubble
X-linked severe combined immunodeficiency (X-SCID, or SCID-X1), is an orphan monogenic disorder popularly known as ‘bubble boy disease’ that affects 1 in 50,000-100,000 live births. The most serious of all primary immunodeficiencies, X-SCID causes severe failure of the immune system, including a lack of T cells, natural killer (NK) cells, or functional B cells. For...
30
May
2019